News
Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...
Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...
Shipments to China are now paused through the end of 2025, dragging global sales of the HPV vaccine down 55% last quarter.
1d
Irish Examiner on MSNMSD plans $3bn cuts amid competition for Irish-manufactured cancer drug KeytrudaMSD is slashing $3bn (€2.59bn) from its annual spending as it braces for off-brand competition to its Irish-manufactured ...
Merck is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the ...
Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...
Merck (MRK) is cutting $3 billion from its annual expenses as it prepares for generic competition to its blockbuster cancer drug, Keytruda.
Merck & Co said on Tuesday it was extending its hold on Gardasil shipments to China until at least the end of 2025 due to ...
7d
Zacks.com on MSNWill Keytruda Continue to Aid MRK's Top Line Ahead of Q2 Earnings?In the last reported quarter, U.S. sales of Keytruda were negatively impacted by around $250 million due to the timing of ...
This month, Trump threatened 200% tariffs on imported medicines. Last weekend, he agreed to a much lower 15% tariff on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results